Kornimate/medical-research-clean huggingface dataset:
diagnostic screening tests and potential biomarkers in mitochondrial myopathies

Conditions: Mitochondrial Myopathies; Healthy Controls

Summary: the purpose of this study is to develop simple diagnostic screeningtests and investigate potential biomarkers for identifying patients with abnormalities of mitochondrial function, which also can be used as outcome measures in future clinical trials. the study will investigate two submaximal tests: a submaximal handgrip test and a walking test. furthermore investigators will investigate acyl-carnitine profiles and gdf-15 levels in patients with mitochondrial myopathy.


Eligibility criteria:
inclusion criteria: * age 18-75 * verified mitochondrial myopathy * or healthy control * or disease control (another neuromuscular disease) exclusion criteria: * patient has any prior or current medical conditions that, in the judgment of the investigator, would prevent the patient from safely participating in and/or completing all study requirements. * patient has symptoms of mitochondrial myopathy due to known secondary mitochondrial dysfunction * patient does not have the cognitive capacity to understand/comprehend and complete all study assessments. * pregnancy or breastfeeding.
the diagnostic yield and safety of transbronchial cryobiopsy in different freezing time in the diffuse parenchymal lung diseases

Conditions: Transbronchial Cryobiopsy; Freezing Time; Diagnostic Yield; Safety

Summary: transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.

transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety. this is a prospective randomized control trial.

Eligibility criteria:
inclusion criteria: 1. the patients are admitted in the institution as dpld, while undefined after thorough history collection, laboratory examination and radiological data. 2. transbronchial cryobiopsy(tbcb) is indicated by clinicians for definitive diagnosis and patients are content with the examination with agreement signed. 3. blood gas analysis, routine blood test, ecg examination, coagulation function, immunological examination, chest hrct, and liver/kidney function test have been completed. exclusion criteria: 1. the radiological data indicates non-dpld 2. the clinical examinations mentioned above are not completed. 3. the patient cannot endure or does not agree the procedure.

Keywords: transbronchial cryobiopsy freezing time diagnostic yield safety diffuse parenchymal lung disease
yoga for youth with ibd: a pilot feasibility study

Conditions: Inflammatory Bowel Diseases; Yoga; Adolescents; Crohn Disease; Ulcerative Colitis

Summary: an 8-week yoga intervention to determine the feasibility and acceptability of yoga as a supplemental therapy in the management of inflammatory bowel disease in the adolescent population.

youth with ibd experience abdominal pain, diarrhea, weight loss, and psychological suffering related to their disease process. while many biologic and non-biologic therapies are available to target the inflammatory component of ibd, youth with ibd could benefit from a more holistic therapy that addresses psychological wellness, which has been shown, in turn, to reduce disease burden. it is known that stress (multiple varieties) leads to ibd flares. it is also known that mind-body intervention reduces stress. the mind-gut connection is widely discussed in medical circles, however, current therapies have not capitalized on it. the investigators would like to know if an easily accessible mind-body intervention (yoga) can improve wellness, lower stress levels, and reduce intestinal inflammation in youth with ibd. the study will be an 8-week feasibility pilot. participants will be asked to participate in online yoga videos and in-studio yoga sessions. participants will be asked to complete multiple surveys throughout the intervention and continue receiving standard care from their primary gastroenterology team.

Eligibility criteria:
inclusion criteria: * age 10-21 * diagnosis of crohn's disease or ulcerative colitis * patient of a stanford children's health or stanford-affiliated pediatric gastroenterologist * ability to attend in-person meetings/training exclusion criteria: * initiation of biologic therapy in prior 3 months * hospital admission in prior 2 months * major surgery in prior 1 month * pucai/pcdai \>65 * current pregnancy * severe developmental or intellectual disability * non-english speaking * not participating in another concurrent clinical trial

Keywords: inflammatory bowel disease adolescent yoga mind-body
evaluation of digital stabilizing splint in management of masticatory muscle disorder

Conditions: Muscle Disorder

Summary: the goal of this clinical trial is to evaluate the digital stabilizing splint in management of masticatory muscle disorder. the main question it aims to answer are: • is the digital stabilizing splint effective in treatment of masticatory muscle disorder signs and symptoms after 3 months follow up ? participants will be asked to ware the splint and progressively increasing the duration of splint wear, starting from 8 hours per day for 3 months .

the current research was conducted for evaluation of the digital stabilizing splint in the management of masticatory muscle disorder. subjects and methods: eight patients over the age of 18 with masticatory muscle disorders received treatment using a stabilizing splint that was digitally created. the each patient's response to therapy modifications was assessed and compared before and after splint insertion for each patient subjective symptoms were assessed using a patient questionnaire that was repeated before treatment (baseline), one month, and 3 months post-insertion. moreover, the masseter and temporalis muscles' electrical activity was measured using electromyography at baseline and after three months.post-splint insertion. clinical signs such as mouth-opening lateral movements and protrusive movements were measured before and 3 months after the splint was inserted.

Eligibility criteria:
inclusion criteria 1-anterior disc displacement without reduction or osteoarthritis cases 2-pain and/or tenderness of masticatory muscles exclusion criteria 1. absence of previous occlusal splint therapy. 2. absence of apparent dental or periodontal diseases. 3. patients having full or partial dentures that would compromise the support of an occlusal splint were excluded. 4. patient taking analgesics, muscle relaxants, or anti-inflammatory medications will not be included because they may affect the outcome. 5. patients with multiple teeth loss that affects occlusal splint support were excluded.
safety and pharmacokinetics of kbpa-101 in hospital acquired pneumonia caused by o11 pseudomonas aeruginosa

Conditions: Pneumonia; Ventilator Associated Pneumonia

Summary: the objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have hap caused by pseudomonas aeruginosa serotype o11 after three separate administrations of kbpa-101 every third day in addition of standard of care antibiotic treatment.

hospital acquired pneumonia (hap) is a pneumonia occurring 48 hours or more after hospital admission. hap occurs in patients on conventional hospital wards and in intensive care units (icu), some of them associated to mechanical ventilation, known as ventilator associated pneumonia (vap). vap is the most common infection on intensive care units representing 82% of hap cases. pseudomonas aeruginosa is one of the most frequent pathogens involved in icu-hap and despite of adequate treatment its crude mortality remains as high as 70% of the cases.

Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age * patients under intensive care management with hospital acquired pneumonia * microbiological diagnosis of p. aeruginosa serotype o11 hap by lower respiratory tract specimen (bal or minibal) and presence of a new or progressing pulmonary infiltrate, plus one of the three following criteria: a) fever greater than 38ºc, b) wbc greater than 10,000/mm3, or c) purulent sputum * in non-intubated patients confirmed microbiological diagnosis of p. aeruginosa serotype o11 hap by endotracheal aspirate (eta) and modified clinical pulmonary infection score (cpis) higher than 6 points * patient is expected to survive longer than 72 hours * written informed consent provided by the patient or by the relatives or the designated trusted person exclusion criteria: * use of any investigational drug within 30 days preceding the first dose of kbpa-101, or planned use during the study and safety follow-up periods * existence of any surgical or medical condition that might render the patient unduly susceptible to possible toxicity from the monoclonal antibody, including septic shock with unstable hemodynamics, * patients with a known complement deficiency associated with systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, hereditary angioedema, membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent neisserial infections * confirmed human immunodeficiency virus (hiv) infection * transplant patients and/or simultaneous treatment with systemic immuno-suppressive drugs. * patients with a known liver function deficiency, e.g. associated with liver cirrhosis (child pugh b or c) or acute hepatitis * administration of poly- or mono-immunoglobulins within the three months preceding the first dose of study drug or planned administration during the study period * neutropenia

Keywords: pneumonia nosocomial pneumonia pseudomonas aeruginosa monoclonal antibody hospital-acquired pneumonia
maintenance of benefit with atomoxetine hydrochloride in adolescents with adhd

Conditions: Attention-Deficit/Hyperactivity Disorder

Summary: the purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with adhd after 8 weeks and after 52 weeks


Eligibility criteria:
inclusion criteria: * patients must have adhd. * must be 13-16 years of age. * must be able to swallow capsules. * expected to achieve score of 70 or more on iq test * willing and reliable to keep appts. for clinic visits and test exclusion criteria: * treatment within last 30 days with a drug that has not received regulatory approval for any indication. * patients who weigh less than 40 kg or greater than 70 kg. * patients with documented history of bipolar i or ii disorder, or psychosis * patients with documented history of autism, asperger's syndrome or pervasive developmental disorder
malnutrition in gastroenterology patients

Conditions: Malnutrition

Summary: background: malnutrition is frequently occurring in sick patients and is associated with a higher morbidity and mortality. muscle dysfunction is a common finding in malnutrition which leads to a reduced functional status and quality of life. specific aims: the purpose of the study is to evaluate the effect of a three month nutritional intervention with oral supplements on nutritional status, muscle function and quality of life.


Eligibility criteria:
inclusion criteria: * malnutrition * benign disease exclusion criteria: * malignant disease
prize reinforcement contingency management for cocaine dependence: a 24-week randomized controlled trial

Conditions: Cocaine-related Disorders

Summary: the purpose of this study is to determine whether prize-based contingency management (prizecm) combined with cognitive behavioral therapy (cbt) is more effective in the treatment of of cocaine-dependent patients compared to cbt only. patients were randomized to prizecm + cbt (experimental group) or to cbt (control group) an treated over 24 weeks. it is the first trial of this type in europe.


Eligibility criteria:
inclusion criteria: * cocaine dependence, aged 18 or older, other dependences exclusion criteria: * severe somatic, brain, or psychiatric disease, attention deficit disorders with medication methylphenidate
asl in brain metastasis mri following gamma knife treatment

Conditions: Brain Metastases

Summary: arterial spin labeling (asl) is a non-invasive mri technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. the primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of asl in brain metastases suspected of progression/radionecrosis after gk treatment

the metastasis progression versus radionecrosis following gk treatment can sometimes be difficult to distinguish. 60 patients will be included in this prospective, monocentric study. 3 mri (baseline, 1month and 6 month follow-ups) will be performed. two neuroradiologists will blindly analyse the mris comparing asl sensibility and specificity to the standard morphological evaluation and t2 perfusion.

Eligibility criteria:
inclusion criteria: * brain metastasis from histologically proven tumor * gk treatment within 4 month prior to the inclusion * lesions suspected of progression/ radionecrosis : i.e.≥ 25% of the size progression * lesion size: gadolinium enhanced part of the tumour ≥1 cm exclusion criteria: * pregnancy * medical history of primitive brain tumour * mri incompatibility/ medical history of contrast agent allergy * claustrophobia * patient unable to consent * epilepsia/recent stroke * patients participating in other studies * patients without health care insurance

Keywords: asl mri metastasis gamma knife radionecrosis
study of a screening blood test to determine patients' potential risk of adenomatous or advanced colon polyps (acps)

Conditions: Colonic Polyp

Summary: the aim of this study is to develop a blood test to determine which patients are at risk for pre-cancerous colon polyps (acps: advanced colon polyps). the telomere length of peripheral blood lymphocytes (pbls) can be measured from a blood sample. mechanistic pathways and the investigator's preliminary data support pbl telomere length as a biomarker for acps. the long-term goal of this project is to decrease deaths from colon cancer by using a blood test to target colonoscopy for those patients who are at high risk for pre-cancerous polyps.

telomeres are the repetitive dna sequences that cap both ends of chromosomes. shortening of peripheral blood lymphocyte (pbl) telomeres has been associated with renal and other cancers. the investigators' preliminary data shows an association between shorter pbl telomere length and acps. i. specific aims 1. develop a dna and data repository from individuals with advanced colon polyps (acps) and controls 2. confirm that individuals 50 to 60 years of age with acps tend to have shorter peripheral blood lymphocyte (pbl) telomeres than those without acps 3. identify a potential optimal pbl telomere length cut-off to differentiate between individuals with acps and those without for evaluation in a larger scale study the over reaching long term goal is to decrease disease and death from colorectal cancer (crc) using a biomarker strategy to target colonoscopy to those at higher risk.

Eligibility criteria:
inclusion criteria: advanced colon polyp group (acp): * must be 50 to 60 years of age with an advanced colon polyp (acp: advanced colon polyps are those larger than 10 mm, or a colon polyp with high grade dysplasia, or a colon polyp with villous features. control group (controls): * must be 50 to 60 years of age and have had a negative screening colonoscopy. * controls will also have no history of adenomatous colorectal neoplasia. exclusion criteria: * subjects under 50 years of age * subjects over 60 years of age * subjects with colon polyps less than 10 mm in size

Keywords: advanced colon polyp adenomatous colon polyp adenoma, villous colon polyp advanced colorectal adenomas colonic neoplasms high grade dysplasia telomere blood testing
egfr cart cells for patients with metastatic colorectal cancer

Conditions: EGFR-positive Colorectal Cancer

Summary: this is a clinical study to observe the maximum tolerated dose (mtd) and the safety and feasibility of chimeric antigen receptor egfr (egfr cart) cells in metastatic patients with colorectal cancer.

this is a study for the patients with colorectal cancer. maximum tolerated dose climbing test is expected into the group of 9 cases of patients. and phase ii expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. subjects will be collected their t cells and modify them, the modification is a genetic change, that egfr:4-1bb:cd28:cd3 modified t cells, in order to tells the t cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. the cart cells will then be expanded in vitro and then administered to subjects. the purpose of this study is observe the mtd and to assess the safety and feasibility of cart cells in the patients with metastatic colorectal cancer.

Eligibility criteria:
inclusion criteria: * 1. patients must be 18 years to 70 years; * 2. clinical diagnosis of egfr positive for patients with metastatic colorectal cancer; * 3. patients must have a kps of \>80, expected survival \> 3 months; * 4. patients must have at least one measurable lesions; * 5. recently did not use glucocorticoid; * 6. patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: wbc ≥ 4.0×109/l, hb ≥90 g/l, plt ≥100×109/l）; ast ≤2.5uln，alt ≤ 2.5uln; cr≤ 3uln; tbil≤ 3uln， * 7. patients must have a good heart function (lvef\>50%) ; * 8. patients must be willing to practice birth control during and for three months following treatment.note:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment； * 9. patients must be willing to sign an informed consent. exclusion criteria: * 1. patients with other cancer history; * 2. patients allergic to cetuximab; * 3. patients with severe bronchitis, bronchial asthma, or severs pneumonia; * 4. patients with uncontrolled active infections (bacteria, viruses or fungi infection) ; * 5. patients with acute and chronic gvhd (graft versus host disease) * 6. patients with severe autoimmune diseases; * 7. previously treatment with t cell inhibitors (cyclophosphamide, fk506); * 8. patients with active hepatitis b or hepatitis c infection, hiv infection, syphilis serology reaction positive; * 9. patients who are participating or participated any other clinical research in the past 1 months; * 10. pregnant and/or lactating women will be excluded;
a study of arry-371797 in subjects undergoing third molar extraction

Conditions: Dental Pain

Summary: this is a phase 2 study designed to test the ability of investigational study drug arry-371797 to reduce pain either perioperatively or postoperatively in a third molar extraction pain model, and to further evaluate the drug's safety. approximately 150 subjects from the us will be enrolled in this study.


Eligibility criteria:
key inclusion criteria: * scheduled for outpatient oral surgical procedure to remove 2 ipsilateral third molars, at least 1 of which is mandibular and fully or partially impacted by bone. * females of childbearing potential must be willing to use an acceptable method of contraception within 14 days prior to first dose of study drug until the completion of the follow-up procedures. * body weight \>50 kg (110 lbs). * good health determined by medical history, physical examination, vital signs and clinical laboratory results of non-clinical significance. * additional criteria exist. key exclusion criteria: * positive urine drug screen. * use of prescription or nonprescription drugs, herbal or dietary supplements, vitamins, or grapefruit juice within 14 days prior to first dose of study drug. * additional criteria exist.

Keywords: analgesia
research on intraoperative hypothermia risk prediction model and temperature management strategy for elderly patients during surgery based on dynamic incremental training

Conditions: Intraoperative Hypothermia

Summary: with the support of partial dual temperature monitoring (comparing the specific difference between standardized axillary temperature monitoring and esophageal temperature), this trial is divided into the following three parts: 1. multi center observational study: establish and validate a dynamic incremental training intraoperative hypothermia prediction model - intelligent care for the elderly (ice) - intraoperative hypothermia warning system, and provide ice offline for use by healthcare professionals and ice online for further model updates when needed for clinical or research purposes. 2. multi center non randomized controlled clinical trial: conduct a multi center stratified temperature management clinical trial based on ice offline after dynamic incremental training to verify the clinical and economic benefits of the model and active warming. 3. pre and post comparative study: collect data before ice application and compare it with data after ice promotion.


Eligibility criteria:
inclusion criteria: * elderly patients (aged 60 and above) undergoing non cardiac elective surgery under general anesthesia; * surgical duration ≥ 30 minutes; * normal preoperative bleeding and clotting time * american society of aneshesiologists physical status classification system:ⅰ～ⅳ exclusion criteria: * mental illness * cirrhosis * existence or potential central hyperthermia * metabolic thermoregulatory abnormalities * history of malignant hyperthermia or family history * extensive skin burns or injuries * seriously infect * long term use of nonsteroidal anti-inflammatory drugs * expected difficult airway * researchers believe that individuals who are not suitable to participate in clinical trial * refusal to sign informed consent form * withdraw informed consent form * severe bleeding or shock during perioperative period.

Keywords: intraoperative hypothermia prediction model elderly patients active warming machine learning
laparascopic keyhole vs sugarbaker repair in parastomal hernia

Conditions: Parastomal Hernia

Summary: this is a non-randomised case-controlled prospective study of consecutive patients with parastomal hernia, comparing the laparoscopic keyhole repair with the modified sugarbaker repair.

objective: to compare the laparoscopic keyhole repair with the modified sugarbaker repair in a nonrandomised case-controlled prospective study of consecutive patients with parastomal hernia. summary background data: two reviews of uncontrolled studies concluded that the sugarbaker repair is superior to the keyhole repair. the present study challenges the claim. methods: in two time periods 135 patients with a parastomal hernia were repaired with the keyhole technique (74 patients, using a two-layer mesh of polypropylene and eptfe with a self-cut slit, 1997- 2009) or the sugarbaker technique (61 patients, using a coated polypropylene mesh, 2009-2015). the patients in the two groups matched with regard to age, gender, asa score, colostomy or ileostomy hernia, previous repairs, size of fascial defect and simultaneous repair of a concurrent incisional hernia. observation time was defined as time to recurrence, stoma re-siting, mesh removal, death, or last non-event visit

Eligibility criteria:
inclusion criteria: patients with a diagnosis of parastomal hernia and indication for surgical treatment - exclusion criteria: none -